Can a new pill tame ulcerative colitis when others fail?

NCT ID NCT07747155

Not yet recruiting Disease control Sponsor: Pyrotech Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This trial is testing an experimental oral drug called PTT-621 in adults aged 18-70 with moderate-to-severe ulcerative colitis who haven't responded well to standard treatments. Participants will take PTT-621 tablets for 12 weeks. The main goal is to see if the drug can improve the lining of the colon, with secondary goals of assessing safety, symptom relief, and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PTT-621 tablets (an experimental oral drug)
What this could lead to: If successful, PTT-621 could offer a new oral treatment option for people with moderate-to-severe ulcerative colitis who haven't found relief from current therapies.
What could go wrong: This is an early-stage (Phase IIa) study with only 40 participants, so results may not apply to everyone. The drug's safety and effectiveness are not yet proven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

Renji Hospital-Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.